Century Communities To Host June Ribbon-Cutting at Running Creek in Locust, NC
Event to be held on June 26, featuring model tours, move-in ready homes, and giveaways
CHARLOTTE, N.C., June 12, 2025 /PRNewswire/ — Century Communities, Inc.—a top 10 national homebuilder, industry leader in online home sales, and the highest-ranked homebuilder on Newsweek's list of America's Most Trustworthy Companies 2025—announced Running Creek, the Company's new community in Locust, NC, will host a ribbon-cutting ceremony with the Stanly County Chamber of Commerce on Thursday, June 26 from 11 a.m. to 1 p.m.
The Grand Opening event will include a tour of the community's new model home—featuring the beautiful Red Cedar floor plan—a showcase of move-in ready homes at Running Creek, and special savings for early homebuyers. Attendees will also have a chance to win a round of golf for two at Red Bridge Golf Club and a gift card for The Rustic at Dennis Vineyards.
Learn about pre-Grand Opening opportunities and sign up to attend the ribbon-cutting at www.CenturyCommunities.com/RunningCreekNC.
'We're proud to officially launch Running Creek as our newest community in the Charlotte area,' said Scott Herr, Charlotte Division President. 'With beautiful floor plans on generous homesites, Running Creek offers elevated country living with convenient proximity to Charlotte.'
MORE ABOUT RUNNING CREEKNow selling from the high $400s
Single-family floor plans on 0.69-acre+ lots
Spacious two-story layouts
3 to 4 bedrooms, 3 to 4 bathrooms, 2-bay garages
2,447 to 2,892 square feet
Quartz countertops, stainless-steel appliances, 42″ cabinets and more included
Cul-de-sac homesites available
Plans with studies and lofts available
Convenient access to Concord, Kannapolis, Mint Hill, and Charlotte
Close to Lake Tillery, Morrow Mountain State Park, and Uwharrie National Forest
Minutes from hotspots like downtown Locust
Location:21023 Running Creek Church DriveLocust, NC 28097704.444.0046
COMING SOON!Meadow Creek Village in LocustMinutes from Running Creek, Meadow Creek Village is anticipated to open this summer.
Learn more and join the interest list at www.CenturyCommunities.com/MeadowCreekVillageNC.
DISCOVER THE FREEDOM OF ONLINE HOMEBUYING:
Century Communities is proud to feature its industry-first online homebuying experience on all available homes in North Carolina.
How it works:
Shop homes at CenturyCommunities.com
Click 'Buy Now' on any available home
Fill out a quick Buy Online form
Electronically submit an initial earnest money deposit
Electronically sign a purchase contract via DocuSign®
Learn more about the Buy Online experience at www.CenturyCommunities.com/online-homebuying.
About Century CommunitiesCentury Communities, Inc. (NYSE: CCS) is one of the nation's largest homebuilders, an industry leader in online home sales, and one of the highest-ranked homebuilders on Newsweek's list of America's Most Trustworthy Companies 2025—consecutively awarded for a third year—and Newsweek's list of the World's Most Trustworthy Companies 2024. Through its Century Communities and Century Complete brands, Century's mission is to build attractive, high-quality homes at affordable prices to provide its valued customers with A HOME FOR EVERY DREAM®. Century is engaged in all aspects of homebuilding — including the acquisition, entitlement and development of land, along with the construction, innovative marketing and sale of quality homes designed to appeal to a wide range of homebuyers. The Company operates in 17 states and over 45 markets across the U.S., and also offers mortgage, title, insurance brokerage, and escrow services in select markets through its Inspire Home Loans, Parkway Title, IHL Home Insurance Agency, and IHL Escrow subsidiaries. To learn more about Century Communities, please visit www.centurycommunities.com.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Star
6 hours ago
- The Star
Investors to focus on geopolitics, US economic data this week
Traders work on the floor at the New York Stock Exchange (NYSE) in New York, US, on Monday, May 19, 2025.- Photographer: Michael Nagle/Bloomberg NEW YORK: Investors will focus on the Israel-Iran conflict and US economic data releases this week to assess the near-term outlook for stocks, as the S&P 500 hovers just below its February highs. The S&P 500 has rebounded sharply from its early-April sell-off, as tariff-related tensions have eased. However, the US benchmark index appears to be taking a breather at some 2.7% below its February closing high. The index has gone 27 trading sessions since coming within 5% of its February high but has not yet set a new record. With Israel and Iran trading missiles, escalating threats of a sweeping conflict in the Middle East sent oil prices sharply higher and led to caution in global markets. 'We're all waiting on pins and needles to see what happens with the Israel-Iran situation,' said Brian Jacobsen, chief economist at Annex Wealth Management. So far, the oil market has absorbed most of the impact from geopolitical turmoil, with equities relatively stable. Yet stock investors remain concerned that higher oil prices could stoke inflation and upset plans for interest rate cuts from the US Federal Reserve (Fed). Last Wednesday, the Fed held rates steady and the central bank's policymakers signalled borrowing costs are still likely to fall this year. But they estimated the overall pace of expected future rate cuts would be slower than they saw at their last meeting in March. They cited expectations that higher inflation would flow from President Donald Trump's tariff plans. 'The question is oil prices and what that does to inflation – which has implications for monetary policy and how long the Fed keeps rates 'meaningfully restrictive',' said Sonu Varghese, global macro strategist at financial services company Carson Group. The big near-term risk for equities, investors said, was the effects of the United States joining Israel's bombing campaign against arch-enemy Iran. The US joined Israel's bombardment of Iranian nuclear and missile sites last Saturday, as residents of Iran's capital Tehran streamed out of the city on the sixth day of the air assault. The White House had said last Thursday that Trump would decide on US action in the next two weeks. 'The US entry into the war or further escalation in the attacks between the two countries, that would give the S&P 500 and equity markets more reasons to react negatively,' said Damian McIntyre, head of multi-asset solutions at investment management company Federated Hermes in Pittsburgh. On the other hand, a de-escalation in Middle East tensions could prompt a relief rally for stocks. 'If both sides can kind of just slowly de-escalate, that would be positive for equity markets, positive for risk markets,' McIntyre said. 'Markets are taking a bit of a wait-and-see approach here,' he said. Still, any stock market pull-backs due to rising geopolitical tensions are likely to be fleeting, investors said. 'History says that usually military shocks are shallow and short-lived, and so until further notice, I think that's how Wall Street will react to this one,' Sam Stovall, chief investment strategist at CFRA Research, said. Investors will also parse a slew of incoming data releases, including US business activity and housing sales today, consumer confidence numbers tomorrow and the Personal Consumption Expenditures Price Index on Friday. US consumer confidence plunged in the past few months, with households fearing tariffs could prompt a recession and higher inflation. However, with inflation in check and the United States reaching a truce in its trade fight with China, investors expect to see a pickup in sentiment. 'Remember, the survey-based data all got crushed in the March, April, May time frame. My expectation is we're still going to see an improvement,' Mark Hackett, chief market strategist at Nationwide said. — Reuters
Malaysian Reserve
2 days ago
- Malaysian Reserve
Halozyme Announces argenx Received European Commission Approval for VYVGART® Subcutaneous Injection with ENHANZE® for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
SC injection of VYVGART® is available as a vial or prefilled syringe and can be administered by a patient, caregiver, or healthcare professional SAN DIEGO, June 20, 2025 /PRNewswire/ — Halozyme Therapeutics, Inc. (NASDAQ: HALO) (Halozyme) today announced that argenx received European Commission (EC) approval of VYVGART® 1000mg (efgartigimod alfa) developed with ENHANZE®, Halozyme's proprietary recombinant human hyaluronidase enzyme (rHuPH20), for subcutaneous (SC) injection as a monotherapy for the treatment of adult patients with progressive or relapsing active chronic inflammatory demyelinating polyneuropathy (CIDP) after prior treatment with corticosteroids or immunoglobulins. VYVGART is the first and only targeted IgG Fc-antibody fragment for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) and the first novel mechanism of action for CIDP treatment in more than 30 years. 'We are pleased to announce the European Commission approval of the subcutaneous injection of VYVGART, which is co-formulated with our ENHANZE drug delivery technology for use in CIDP patients. This marks another milestone in our partnership with argenx and the expansion of access to Europe is another catalyst supporting our growth,' said Dr. Helen Torley, president and chief executive officer of Halozyme. The EC decision is based on positive results from the ADHERE clinical trial, the largest study of CIDP patients to date. For more information on the study and its findings, please view argenx's press release issued on June 20, 2025. The approval by the EC is valid in all 27 European Union (EU) Member States, as well as Iceland, Norway and Liechtenstein. About Halozyme Halozyme is a biopharmaceutical company advancing disruptive solutions to improve patient experiences and outcomes for emerging and established therapies. As the innovators of ENHANZE® drug delivery technology with the proprietary enzyme rHuPH20, Halozyme's commercially-validated solution is used to facilitate the subcutaneous delivery of injected drugs and fluids, with the goal of improving the patient experience with rapid subcutaneous delivery and reduced treatment burden. Having touched one million patient lives in post-marketing use in ten commercialized products in at least one major region and across more than 100 global markets, Halozyme has licensed its ENHANZE® technology to leading pharmaceutical and biotechnology companies including Roche, Takeda, Pfizer, Janssen, AbbVie, Eli Lilly, Bristol-Myers Squibb, argenx, ViiV Healthcare, Chugai Pharmaceutical and Acumen Pharmaceuticals. Halozyme also develops, manufactures and commercializes, for itself or with partners, drug-device combination products using its advanced auto-injector technologies that are designed to provide commercial or functional advantages such as improved convenience, reliability and tolerability, and enhanced patient comfort and adherence. The Company has two commercial proprietary products, Hylenex® and XYOSTED®, partnered commercial products and ongoing product development programs with Teva Pharmaceuticals and McDermott Laboratories Limited, an affiliate of Viatris Inc. Halozyme is headquartered in San Diego, CA and has offices in Ewing, NJ and Minnetonka, MN. Minnetonka is also the site of its operations facility. For more information visit and connect with us on LinkedIn and Twitter. Safe Harbor Statement In addition to historical information, the statements set forth above include forward-looking statements including, without limitation, statements concerning the possible activity, benefits and attributes of ENHANZE®, the possible method of action of ENHANZE®, its potential application to aid in the dispersion and absorption of other injected therapeutic drugs, and statements concerning certain other potential benefits of ENHANZE® including facilitating more rapid delivery of injectable medications through subcutaneous delivery and potentially lowering the treatment burden for patients, including a potential reduction in administration time and broadening the treatment options for the indication referred to in this press release. Forward-looking statements may also include statements regarding potential growth catalysts and opportunities driven by the product development and commercialization efforts of Halozyme's ENHANZE® partners. These forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. The forward-looking statements are typically, but not always, identified through use of the words 'expect,' 'believe,' 'enable,' 'may,' 'will,' 'could,' 'intends,' 'estimate,' 'anticipate,' 'plan,' 'predict,' 'probable,' 'potential,' 'possible,' 'should,' 'continue,' and other words of similar meaning. Actual results could differ materially from the expectations contained in forward-looking statements as a result of several factors, including uncertainties concerning unexpected results or delays in the timing of the Halozyme's expected growth catalysts or in the launch or commercialization of our partner's product for the indication referred to in this press release, unexpected adverse events or patient experiences or outcomes from being treated with the ENHANZE® co-formulated treatment referred to in this press release, and competitive conditions. These and other factors that may result in differences are discussed in greater detail in Halozyme's most recent Annual and Quarterly Reports filed with the Securities and Exchange Commission. Except as required by law, Halozyme undertakes no duty to update forward-looking statements to reflect events after the date of this release. Contacts: Tram BuiVP, Investor Relations and Corporate Communications609-333-7668tbui@ Sydney CharltonTeneo 917-972-8407
Malaysian Reserve
2 days ago
- Malaysian Reserve
Faruqi & Faruqi Reminds Organon Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of July 22, 2025
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Organon To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Organon between October 31, 2024 and April 30, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] NEW YORK, June 20, 2025 /PRNewswire/ — Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Organon & Co. ('Organon' or the 'Company') (NYSE: OGN) and reminds investors of the July 22, 2025 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has recovered hundreds of millions of dollars for investors since its founding in 1995. See Defendants provided investors with material information concerning Organon's prioritization of its capital allocation strategy through regular, quarterly dividends. Defendants' statements included, among other things, reassurance that capital allocation through the aforementioned dividends was a '#1 capital allocation priority' and that Organon was committed to consistent deployment of capital. Defendants provided these overwhelmingly positive statements to investors while, at the same time, disseminating materially false and misleading statements and/or concealing material adverse facts concerning the true state of the Company's priorities, particularly, related to capital allocation through quarterly dividends. Notably, Defendants concealed the high priority of Organon's debt reduction strategy following the Company's acquisition of Dermavant, resulting in a 70% decrease for the regular quarterly dividend. Such statements absent these material facts caused Plaintiff and other shareholders to purchase Organon's securities at artificially inflated prices. Investors and analysts again reacted promptly to Organon's revelations. The price of Organon's common stock declined dramatically. From a closing market price of $12.93 per share on April 30, 2025, Organon's stock price fell to $9.45 per share on May 1, 2025, a decline of more than 27% in the span of just a single day. The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class who is adequate and typical of class members who directs and oversees the litigation on behalf of the putative class. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member. Your ability to share in any recovery is not affected by the decision to serve as a lead plaintiff or not. Faruqi & Faruqi, LLP also encourages anyone with information regarding Organon's conduct to contact the firm, including whistleblowers, former employees, shareholders and others. To learn more about the Organon & Co. class action, go to or call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). Follow us for updates on LinkedIn, on X, or on Facebook. Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP ( Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.
